GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Non-small Cell Lung Cancer;   Head and Neck Squamous Cell Carcinoma;   Renal Cell Carcinoma;   Urinary Bladder Cancer;   Melanoma;   Sarcoma Interventions:   Drug: GI-101;   Drug: Pembrolizumab;   Drug: Lenvatinib;   Radiation: Local Radiotherapy Sponsors:   GI Innovation, Inc.;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials